Ripan Puri CEO Biological E marks a key leadership appointment in India’s pharmaceutical sector as the company strengthens its growth and commercial strategy.
Ripan Puri has been appointed Chief Executive Officer at Biological E Limited, bringing extensive experience in leading large-scale pharma businesses and delivering strong P&L performance.
Leadership transition in pharma
In his new role, Puri will lead the company’s overall strategy, operations, and growth initiatives across key therapeutic and business segments.
His appointment comes at a time when the pharmaceutical industry is witnessing increased focus on scale, innovation, and global expansion.
Strong track record across leading pharma companies
Prior to this, Puri served as Business Director – Pharmaceuticals at Himalaya Wellness Company, where he led the end-to-end pharmaceutical business with full P&L responsibility and was part of the global leadership team.
He has also held senior leadership roles at:
- Boehringer Ingelheim
- Abbott
- Dr Reddy’s Laboratories
- Novartis
- Sanofi
His experience spans cardiology, diabetes, and specialty care segments, along with leading large teams and complex commercial operations.
Driving growth and innovation
The Ripan Puri CEO Biological E development highlights the company’s focus on strengthening leadership to drive growth and expand its presence in the pharmaceutical market.
With deep industry expertise, his leadership is expected to support innovation, commercial expansion, and long-term business performance.
